Study of Potencial Cell Therapy Treated its 20th Patient

0
(0)

news_9-29

Cytori Therapeutics recently announced that its Phase 3 STAR clinical trial, evaluating the efficacy and safety of Cytori Cell Therapy in scleroderma patients with hand impairment, has treated its 20th patient to reach 25 percent of its enrollment and treatment goal. The trial is continuing on the recommendation of an independent monitoring committee that evaluated safety data obtained from the first 10 patients.

The STAR clinical trial (NCT02396238), currently recruiting participants, is a placebo-controlled Phase 3 study of Cytori Cell Therapy (ECCS-50) injected subcutaneously into the fingers of scleroderma patients who have experienced hand dysfunction due to the disease.

Read full article here: http://bit.ly/1VoxBOT

Learn more about scleroderma here: http://bit.ly/learnscleroderma

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?

Leave a Comment

Your email address will not be published. Required fields are marked *